vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from a Phase II trial of the company’s glucokinase activator to treat Type I diabetes could portend further success in a planned pivotal study. The company hopes the therapy, TTP399, can become a first-in-class oral adjunctive treatment to insulin for Type I diabetics.

vTv Therapeutics Inc. (NASDAQ:VTVT) said Monday that TTP399 significantly reduced HbA1c vs. placebo in the second part of the Phase II Simplici-T1 trial at week 12, meeting its primary endpoint (p=0.03). The company is seeking to show that the GCK activator helps maintain glycemic control in the adjunctive setting among adults with the disease...